Remove Containment Remove Hormones Remove Insulin
article thumbnail

Type 1 Diabetes Vaccine: Does Diamyd Have a Winning Formula?

XTalks

In addition to the vaccine, the company is also developing an investigational drug called Remygen for the regeneration of endogenous insulin production and to improve hormonal response to hypoglycemia; trials to test the treatment are currently ongoing in patients that have been living with type 1 diabetes for more than five years.

article thumbnail

FDA Warns About Compounded Versions of Ozempic and Wegovy

XTalks

Ozempic and Wegovy, which contain the active ingredient semaglutide, were approved by the US Food and Drug Administration (FDA). Semaglutide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the GLP-1 hormone released in the gastrointestinal tract after eating. What Should Patients and Healthcare Professionals Know?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes | Eli Lilly and Company

The Pharma Data

The Tempo Pen is a modified version of Lilly ‘s existing prefilled, disposable insulin pen to which the Tempo Smart Button – pending CE (Conformité Européenne or European Conformity) marking – attaches. Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.

Insulin 52
article thumbnail

Top 5 Foods Banned in Europe

XTalks

Parabens, which are also prevalent in cosmetics, can interfere with the regular operation of human hormonal systems, affecting both male and female reproductive health, development, fertility and birth results. There’s been varied research regarding the synthetic hormone’s association with breast cancer.

article thumbnail

Tirzepatide Obesity Drug Shown to Reduce Body Weight by 20 Percent in Eli Lilly Trial

XTalks

Tirzepatide is a novel investigational obesity treatment that contains mimetics of two hormones that are involved in regulating appetite in a single peptide: a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist and a GLP-1 (glucagon-like peptide-1) receptor agonist.

Trials 98
article thumbnail

Alnylam finds belly fat gene and drug target in UK Biobank study

pharmaphorum

Transgenic mice in which the gene has been deleted have improved control of blood glucose and insulin sensitivity. The finding came from an analysis of sequencing data from more than 360,000 individuals in the UK Biobank , which contains genetic and health information from half a million UK participants.

article thumbnail

Creating Future of MedTech Industry with Artificial Intelligence

Delveinsight

The device is worn on the patients’ body, which contains a biharmonic cartridge in it that carries insulin and glucagon. The device can be configured to inject a specific dose of the hormones into the patient. The iLet mimics a biological pancreas and consists of a dual-chamber, autonomous, infusion pump.

Protein 56